Thus, we hypothesized that targeting the FZD1 may open new pharmacological venues for treating cardiac hypertrophy and heart failure after MI to supplement current drugs that target the sympathetic or renin-angiotensin systems. The gene discussed is FZD1; the disease is myocardial infarction.